Epigraph: A vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine

James Theiler, Hyejin Yoon, Karina Yusim, Louis Picker, Klaus Frueh, Bette Korber

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Epigraph is an efficient graph-based algorithm for designing vaccine antigens to optimize potential T-cell epitope (PTE) coverage. Epigraph vaccine antigens are functionally similar to Mosaic vaccines, which have demonstrated effectiveness in preliminary HIV non-human primate studies. In contrast to the Mosaic algorithm, Epigraph is substantially faster, and in restricted cases, provides a mathematically optimal solution. Epigraph furthermore has new features that enable enhanced vaccine design flexibility. These features include the ability to exclude rare epitopes from a design, to optimize population coverage based on inexact epitope matches, and to apply the code to both aligned and unaligned input sequences. Epigraph was developed to provide practical design solutions for two outstanding vaccine problems. The first of these is a personalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellent match to an individual's infecting strain, intended to contain or clear a chronic infection. The second is a pan-filovirus vaccine, with the potential to protect against all known viruses in the Filoviradae family, including ebolaviruses. A web-based interface to run the Epigraph tool suite is available (http://www.HIV.lanl.gov/content/sequence/EPIGRAPH/epigraph.HTML).

Original languageEnglish (US)
Article number33987
JournalScientific Reports
Volume6
DOIs
StatePublished - Oct 5 2016

Fingerprint

AIDS Vaccines
Vaccines
Antigens
Epitopes
Therapeutics
Ebolavirus
HIV
T-Lymphocyte Epitopes
Primates
Viruses
T-Lymphocytes
Infection
Population

ASJC Scopus subject areas

  • General

Cite this

Epigraph : A vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine. / Theiler, James; Yoon, Hyejin; Yusim, Karina; Picker, Louis; Frueh, Klaus; Korber, Bette.

In: Scientific Reports, Vol. 6, 33987, 05.10.2016.

Research output: Contribution to journalArticle

@article{0d4f6f5d31fc4fbd9c3076668958db15,
title = "Epigraph: A vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine",
abstract = "Epigraph is an efficient graph-based algorithm for designing vaccine antigens to optimize potential T-cell epitope (PTE) coverage. Epigraph vaccine antigens are functionally similar to Mosaic vaccines, which have demonstrated effectiveness in preliminary HIV non-human primate studies. In contrast to the Mosaic algorithm, Epigraph is substantially faster, and in restricted cases, provides a mathematically optimal solution. Epigraph furthermore has new features that enable enhanced vaccine design flexibility. These features include the ability to exclude rare epitopes from a design, to optimize population coverage based on inexact epitope matches, and to apply the code to both aligned and unaligned input sequences. Epigraph was developed to provide practical design solutions for two outstanding vaccine problems. The first of these is a personalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellent match to an individual's infecting strain, intended to contain or clear a chronic infection. The second is a pan-filovirus vaccine, with the potential to protect against all known viruses in the Filoviradae family, including ebolaviruses. A web-based interface to run the Epigraph tool suite is available (http://www.HIV.lanl.gov/content/sequence/EPIGRAPH/epigraph.HTML).",
author = "James Theiler and Hyejin Yoon and Karina Yusim and Louis Picker and Klaus Frueh and Bette Korber",
year = "2016",
month = "10",
day = "5",
doi = "10.1038/srep33987",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Epigraph

T2 - A vaccine design tool applied to an HIV therapeutic vaccine and a pan-filovirus vaccine

AU - Theiler, James

AU - Yoon, Hyejin

AU - Yusim, Karina

AU - Picker, Louis

AU - Frueh, Klaus

AU - Korber, Bette

PY - 2016/10/5

Y1 - 2016/10/5

N2 - Epigraph is an efficient graph-based algorithm for designing vaccine antigens to optimize potential T-cell epitope (PTE) coverage. Epigraph vaccine antigens are functionally similar to Mosaic vaccines, which have demonstrated effectiveness in preliminary HIV non-human primate studies. In contrast to the Mosaic algorithm, Epigraph is substantially faster, and in restricted cases, provides a mathematically optimal solution. Epigraph furthermore has new features that enable enhanced vaccine design flexibility. These features include the ability to exclude rare epitopes from a design, to optimize population coverage based on inexact epitope matches, and to apply the code to both aligned and unaligned input sequences. Epigraph was developed to provide practical design solutions for two outstanding vaccine problems. The first of these is a personalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellent match to an individual's infecting strain, intended to contain or clear a chronic infection. The second is a pan-filovirus vaccine, with the potential to protect against all known viruses in the Filoviradae family, including ebolaviruses. A web-based interface to run the Epigraph tool suite is available (http://www.HIV.lanl.gov/content/sequence/EPIGRAPH/epigraph.HTML).

AB - Epigraph is an efficient graph-based algorithm for designing vaccine antigens to optimize potential T-cell epitope (PTE) coverage. Epigraph vaccine antigens are functionally similar to Mosaic vaccines, which have demonstrated effectiveness in preliminary HIV non-human primate studies. In contrast to the Mosaic algorithm, Epigraph is substantially faster, and in restricted cases, provides a mathematically optimal solution. Epigraph furthermore has new features that enable enhanced vaccine design flexibility. These features include the ability to exclude rare epitopes from a design, to optimize population coverage based on inexact epitope matches, and to apply the code to both aligned and unaligned input sequences. Epigraph was developed to provide practical design solutions for two outstanding vaccine problems. The first of these is a personalized approach to a therapeutic T-cell HIV vaccine that would provide antigens with an excellent match to an individual's infecting strain, intended to contain or clear a chronic infection. The second is a pan-filovirus vaccine, with the potential to protect against all known viruses in the Filoviradae family, including ebolaviruses. A web-based interface to run the Epigraph tool suite is available (http://www.HIV.lanl.gov/content/sequence/EPIGRAPH/epigraph.HTML).

UR - http://www.scopus.com/inward/record.url?scp=84990196396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990196396&partnerID=8YFLogxK

U2 - 10.1038/srep33987

DO - 10.1038/srep33987

M3 - Article

C2 - 27703185

AN - SCOPUS:84990196396

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 33987

ER -